Alarmins are endogenous mediators that are elicited rapidly in response to danger signals, enhancing innate and adaptive immune responses by promoting the recruitment and maturation of antigen-presenting cells (APCs). The nucleosome-binding protein HMGN1 is a potent alarmin that binds TLR4 and induces antigen-specific Th1 immune responses, but its contributions to antitumor immunity have not been explored. We found that ovalbumin (OVA)-expressing EG7 mouse thymoma cells grew much faster in Hmgn1-deficient mice than littermate-matched controls. Tumor-bearing Hmgn1 -/-mice generated fewer OVAspecific CD8 cells in the spleen than EG7-bearing Hmgn1 +/+ mice, suggesting that HMGN1 supported T cell-mediated antitumor immunity. Additionally, EG7 tumors expressing HMGN1grew more slowly than control EG7 tumors, suggesting greater resistance to HMGN1-expressing tumors. This resistance relied on T cell mediated immunity because it was abolished by in vivo depletion of CD4 + and CD8 + T cells. Moreover, Mice vaccinated with a DNA vector expressing an HMGN1-gp100 fusion protein manifested gp100-specific, Th1-polarized immune responses, acquiring resistance to challenge with mouse B16F1 melanoma. Overall, our findings show that HMGN1 contributes to antitumor immunity and it may offer an effective adjuvant to heighten responses to cancer vaccines.
Introduction
In the past two decades, several anti-tumor immunotherapies including adoptive cell therapy, tumor-specific antibodies and checkpoint inhibition have yielded considerable clinical success (1) (2) (3) . Although human papilloma virus (HPV) based vaccines have been successful in cancer prevention, other vaccine approaches have so far failed to mediate regression of solid tumors (3, 4) . There are many hurdles in therapeutic tumor vaccine approaches, predominantly difficulties in inducing sufficient number of antitumor CD8 effector cells and the immunosuppressive tumor microenvironment that inhibits effector mechanisms (5) . 10), whereas -defensins stimulate predominantly Th1 responses upon gene gun delivery to mouse epidermis as a defensin-antigen fusion product (9, 12) . Cathelicidin also promotes the generation of both Th1 and Th2 immune responses when intraperitoneally administered (13).
HMGB1 and HSPs preferentially promote Th1 immune responses involved in protective antitumor immunity (9, 15, 24) . In contrast, eosinophil-derived neurotoxin, a member of the eosinophil-associated ribonuclease, and uric acid selectively enhance the development of Th2 immune responses (14, 21). Therefore, it has gradually become apparent that various alarmins differentially promote distinct types of antigen-specific immune responses. Author Manuscript Published OnlineFirst on September 9, 2014; DOI: 10.1158/0008-5472. CAN-13-2042 Gene gun bullets were prepared as previously described with optimization (26). Briefly, 100 µl of 0.05 M spermidine was added into 45 mg of 1-µm gold beads (Bio-Rad, Hercules, CA) and mixed by brief sonication. Forty-five µl of plasmid (2 mg/ml) was immediately added into the gold/spermidine mixture and the plasmids were coprecipitated onto the gold beads by adding 100 µl of 1 M CaCl 2 drop-wise while vortexing. After washing with 100% ethanol, the plasmid-coated gold beads were resuspended in 6 ml of 100% ethanol in a 15-ml tube and loaded onto pre-dried Teflon tubing (Bio-Rad). The Teflon tubing was rotated at 20 rpm in a Tube turner (Bio-Rad) for 1 minute to allow the gold beads smear evenly on the inner surface of the tubing, and finally was dried by flowing dry nitrogen gas through the rotating tubing at a rate of 0.35 liters/minute for about 4 minutes. The dried tubing was subsequently cut into 0.5-inch sections (bullets) and stored at 4C until use.
For DNA vaccination, C57BL/6 mice were anesthetized and their abdominal skin was shaved. Subsequently, plasmid DNA was delivered into the epidermal layer of the shaved abdominal skin via a Helios Genegun (Bio-Rad, Hercules, CA) with a discharge pressure of 400 psi (4 bullets/mouse/immunization). Mice were vaccinated either once a week for 3 weeks, twice a week for 3 weeks, or only twice in 3 weeks as specified. Each mouse received 4 µg of plasmid DNA at each vaccination.
Mouse tumor models
Mice (C57BL/6, Hmgn1 -/-twice every week. The greatest longitudinal diameter (length) and the greatest transverse diameter (width) of a palpable tumor were measured to the nearest 0.1 mm using a caliper. in FACS buffer and data were acquired on a LSR II flow cytometer (BD). All flow cytometry data were analyzed using FlowJo.
Statistical analysis
Unless otherwise specified, all experiments were performed at least three times, and the results of one representative experiment or the mean of multiple experiments are shown.
Differences in the in vivo tumor growth were determined by Repeated Measures ANOVA, whereas differences between other control groups and experimentally treated groups were evaluated by one way ANOVA after arcsine square-root transformation.
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Exogenous HMGN1 promoted DC activation and host defense against tumor
We next determined whether recombinant human HMGN1 could activate mouse DCs. Mouse
DCs were therefore incubated without (sham) or with human HMGN1 and subsequently The control and HMGN1-expressing EG7 cells were then implanted subcutaneously into C57BL/6 mice and tumor growth was monitored. Control EG7 formed palpable tumors at about two weeks, and progressed during the third weeks after implantation (Fig. 3C ). In contrast, implantation with HMGN1-expressing EG7 cells did not develop palpable tumors within 4 weeks (Fig. 3C ). When mice were followed for longer than four weeks, all mice
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Author Manuscript Published OnlineFirst on September 9, 2014; DOI: 10.1158/0008-5472. CAN-13-2042 inoculated with control EG7 died or became morbid within 5 weeks, whereas 80% of the mice inoculated with HMGN1-expressing EG7 had no or small tumors and remained alive for at least 60 days (Fig. 3D ). Since expression of HMGN1 did not alter the proliferation of HMGN1-expressing EG7 cells in vitro (Fig. 3B) , the failure of implanted HMGN1-expressing EG7 to form tumors was unlikely due to any change in tumorigenecity of the implanted tumor cells. Presumably, human HMGN1 secreted by implanted HMGN1-expressing EG7 tumor cells promoted anti-tumor immune defense.
We also studied whether HMGN1 could promote antitumor defense in the absence of surrogate TAA using HMGN1-expressing EL4 cell lines. Both control and HMGN1-expressing EL4 cell lines grew identically in vitro (sFig. 2A). When implanted into C57BL/6 mice, control EL4 formed rapidly growing tumors, whereas HMGN1-expressing EL4 formed smaller, slowly growing tumors (sFig. 2B). Therefore, HMGN1 induced antitumor defense even in the absence of the potent surrogate TAA OVA.
To investigate whether antitumor immunity was responsible for the observed anti-EG7 resistance (Fig. 3C ), mice inoculated with HMGN1-expressing EG7 cells were depleted of 
HMGN1 acted as an effective adjuvant for induction of anti-melanoma immunity
We evaluated the immunoadjuvant activity of HMGN1 using the rapidly growing mouse B16 melanoma with gp100 as the target TAA. It has previously been shown that covalent linkage of an alarmin to a target TAA can better promote TAA-specific immune responses and immunoprotection (12, 29). Therefore, a series of mammalian expression plasmids encoding HMGN1, gp100, or fusion of HMGN1-gp100 were constructed with the insulin signal peptide (SP) fused in-frame with our target proteins (Fig. 4A) . A flexible linker consisting of three tandems of Gly 4 Ser (12, 29) was introduced between HMGN1 and gp100 in the pcDNA3.1-HMGN1-gp100 plasmid (Fig. 4A ). To confirm that the target gene products could be expressed and secreted by mammalian cells, the supernatants of HEK293 cells transfected with a particular plasmid, were analyzed by Western blot ( and pcDNA3.1-HMGN1-gp100 yielded a detectable protein band of approximately 86-and 102-kDa, respectively, corresponding to the expected size of gp100 and HMGN1-gp100, respectively (Fig. 4B, right panel) . The supernatant of HEK293 cells transfected with pcDNA3.1 plasmid had no positive band as expected (Fig. 4B, right panel) . Further, probing the supernatants of HEK293 cells transiently transfected with pcDNA3.1, pcDNA3.1-gp100, or pcDNA3.1-HMGN1-gp100 with anti-HMGN1 (Fig. 4C, left panel) or anti-gp100 (Fig. 4C 
right panel) revealed a band of approximately 102-kDa for HMGN1-gp100 fusion protein and a band of approximately 86-kDa for gp100 protein (Fig. 4C) . Therefore, the plasmids constructed were indeed capable of directing secreted expression of the target proteins in mammalian cells.
To investigate if HMGN1 could promote an antigen-specific immune response, C57BL/6 mice vaccinated by with various plasmids were analyzed for cytokine-producing T cells in the spleens and draining lymph nodes. Intracellular cytokine staining and flow cytometry analysis (analysis gating illustrated in sFig. 3) showed that in both inguinal lymph nodes and spleen, mice vaccinated with pcDNA3.1-HMGN1-gp100 generated significantly more IFN + CD8 cells than control (vaccinated with pcDNA3.1) mice (Fig. 5) . There was no significant increase in IL-13 + CD8 T cells in the inguinal lymph nodes or spleens of mice vaccinated with pcDNA3.1-HMGN1-gp100 in comparison with the control group (Fig. 5 ). These data demonstrated that the fusion product of HMGN1 and gp100 induced a potent Th1-polarized T cell response against gp100. Mice vaccinated with either pcDNA3.1-HMGN1 or pcDNA3.1-gp100 did not show any increase in the percentage of either IFN + or IL-13 + CD8 T cells, indicating that HMGN1 or gp100 alone had no effect (Fig. 5) . Therefore, HMGN1 acted as an adjuvant to stimulate Th1-polarized gp100-specific immune responses.
We next determined whether DNA vaccination with pcDNA3.1-HMGN1-gp100 could induce sufficiently potent immune responses capable of protecting against a melanoma challenge.
C57BL/6 mice were vaccinated with various plasmids, subcutaneously implanted with B16F1 melanoma, and the appearance and growth of tumors were monitored. Tumors grew at a similar rate in mice vaccinated with pcDNA3.1 (control group) or pcDNA3.1-gp100,
Research. CAN-13-2042 suggesting that vaccination with TAA (gp100) alone had no effect (Fig. 6B) . Although mice vaccinated with pcDNA3.1-HMGN1 showed a slower tumor growth than controls, the difference was not statistically significant (Fig. 6B) . Tumors in mice vaccinated with a mixture of pcDNA3.1-HMGN1 and pcDNA3.1-gp100 grew significantly slower than in the controls, indicative of some immunoprotection (Fig. 6B) . In contrast, none of the mice vaccinated with pcDNA3.1-HMGN1-gp100 either six times or just twice, formed any palpable tumors, indicative of the most potent immunoprotection (Fig. 6B) . Interestingly, mice given the HMGN1-gp100 fusion construct also developed much greater immunoprotection to subsequent B16F1 challenge than mice given a mixture of HMGN1-and gp100-expressing plasmids (Fig. 6B) 
Discussion
HMGN1 is a nuclear protein that binds specifically to nucleosomes and affects chromatin structure and function (30). We have recently reported that extracellular HMGN1 acts as an alarmin and plays a critical role in the induction of antigen-specific immune responses (25).
In this study, we demonstrated the importance of HMGN1 im promoting antitumor immunity in two ways. EG7 tumors grew more rapidly in Hmgn1 -/-mice than in littermate-matched Hmgn1 +/+ mice, which was accompanied by the generation of lower levels of splenic EG7-specific (OVA-specific) CD8 + cells (Fig. 1) . Furthermore, when implanted into C57BL/6 mice, HMGN1-expressing EG7 tumor cells failed to form palpable tumors, whereas control EG7 tumor cells grew progressively into large solid tumors (Fig. 3C) . Depletion of CD4 and CD8 T cells in mice inoculated with HMGN1-expressing EG7 cells nullified the antitumor defense and allowed the mice to grow even larger tumors than mice inoculated with control EG7 cells (Fig. 3E) . Thus, both loss-of-function and gain-of-function approaches demonstrate that HMGN1 is important for the development of antitumor immune defenses.
Knockout of HMGN1 has been shown to affect DNA repair (31) and to cause increased susceptibility to radiation-induced DNA damage as well as tumorigenicity (30, 32).
Therefore, the failure of HMGN1-expressing EG7 to grow into solid tumors might have been due to the adverse growth potential resulting from expression of human HMGN1 in EG7 cells (Fig. 3C ). However, this was considered unlikely for two reasons. One is that pcDNA3.1-HMGN1-hygromycin used for transfecting EG7 cells was constructed to achieve secreted expression of HMGN1 (Fig. 3A) . Consequently, human HMGN1 expressed by transfected EG7 cells would not reach the nucleus. Secondly, since control and HMGN1-expressing EG7
Author Manuscript Published OnlineFirst on September 9, 2014; DOI: 10.1158/0008-5472. CAN-13-2042 cell lines proliferated equally in vitro (Fig. 3B) , the expression of human HMGN1 in EG7 cells did not adversely influence their growth potential. Therefore, implantation of HMGN1-expressing EG7 cells probably enabled the host immune system to develop greater resistance to the tumor cells. This conclusion is supported by data showing that human HMGN1 activated mouse DCs (Fig. 2) , and the induced antitumor defense was dependent on cellmediated immunity (Fig. 3E) .
In this study, human instead of mouse HMGN1 cDNA was used in making various expression constructs. This raises the possibility that adaptive immune responses against xenogenic human HMGN1 instead of antitumor immunity was responsible for the inhibition of HMGN1-expressing EG7 tumors (Fig. 3C, 3D, and 3E ). This was considered unlikely Table 1 ), suggesting that it is unlikely for C57BL/6 mice to mount a CD8 response against human HMGN1.
Since most TAAs are weakly immunogenic, it was relevant to determine if HMGN1 could be used to protect against tumors with weaker TAAs. We therefore investigated whether cutaneous vaccination with a plasmid encoding the expression of a fusion protein consisting of HMGN1 and gp100, a melanoma TAA, could induce gp100-specific CD8 response as well as anti-melanoma protection. Vaccination of C57BL/6 mice with pcDNA3.1-HMGN1-gp100 increased gp100-specific IFN-producing CD8 cells (Fig. 5) . Furthermore, vaccination with pcDNA3.1-HMGN1-gp100 induced full prophylactic protection to a subsequent challenge with mouse B16F1 melanoma (Fig. 6) . It is noteworthy that vaccination with pcDNA3.1-HMGN1-gp100 provided more effective protection than vaccination with a mixture of pcDNA3.1-HMGN1 and pcDNA3.1-gp100 (Fig. 6 ). This was presumably based on observations that antigens linked to mediators capable of interacting with receptors on APCs are more efficiently taken up and processed (9, 33) . 
Secondly, HMGN1 consistently promotes Th1-type immune responses when used intraperitoneally (25) or delivered intradermally as a DNA vaccine (Fig. 5) . This preferential Th1-polarizing capability of HMGN1 makes it highly favorable for inclusion in tumor vaccines since only TAA-specific Th1 type immune responses are protective against tumors.
Thirdly, HMGN1 is more potent and stable compared to other alarmins capable of promoting anti-tumor immune responses. HMGN1 stimulates DC activation at 0.2~1.0 g/ml (approximately 10~60 nM), whereas mouse -defensin 2, heat shock proteins, and HMGB1 need 5-to 10-fold higher concentrations to activate DCs (12, 25, 38-41). Additionally, the presence of intramolecular disulfide bonds in defensins and HMGB1 enables their activities to be affected by their redox status (42, 43) , whereas HMGN1 is consistently active due to the lack of disulfide bond. Although it remains to be determined if HMGN1 can be used to treat established solid tumors, our findings suggest that HMGN1 may potentially be a promising tumor vaccine adjuvant.
